scholarly journals Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening in 1077 Women After BRCA Testing

2013 ◽  
Vol 173 (2) ◽  
pp. 96 ◽  
Author(s):  
Gabriel N. Mannis ◽  
Julia E. Fehniger ◽  
Jennifer S. Creasman ◽  
Vanessa L. Jacoby ◽  
Mary S. Beattie
Maturitas ◽  
2015 ◽  
Vol 80 (3) ◽  
pp. 318-322 ◽  
Author(s):  
Catheleine M.G. van Driel ◽  
Geertruida H. de Bock ◽  
Henriette J.G. Arts ◽  
Aisha S. Sie ◽  
Harry Hollema ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1518-1518
Author(s):  
Laura L. Holman ◽  
Molly S Daniels ◽  
Amanda C. Brandt ◽  
Banu Arun ◽  
Elizabeth Keeler ◽  
...  

1518 Background: We prospectively evaluated the timing and uptake of risk-reducing surgery in a cohort of female BRCA mutation carriers that have no personal cancer history (“previvors”). Methods: Patients at high risk of breast and ovarian cancer were enrolled between 2007 and 2011 and followed in a high-risk ovarian cancer screening clinic. Women were offered risk-reducing salpingo-oophorectomy (RRSO) and/or prophylactic mastectomy (PM) per guidelines. Their clinical data were recorded and analyzed using descriptive statistics. Results: Of 260 BRCA mutation carriers enrolled, 73 have no personal history of cancer and are “previvors.” Patients have been followed for a median of 26.5 months (1-50 months). The median age is 38 years, 81.1% are white, 16.2% are Ashkenazi Jewish, and 79.7% are premenopausal. BRCA1 carriers account for 43.2% of participants and 55.4% have a BRCA2 mutation. The majority of patients (77.6%) presented for ovarian cancer screening <1 year after their BRCA testing. In all, 60.8% of women underwent prophylactic surgery: 28.4% chose RRSO, 18.9% chose PM, and 13.5% chose both procedures. Postmenopausal women were more likely to choose RRSO, while uptake for both procedures was common for premenopausal women (Table, p=0.04). RRSO was also more likely in parous than nulliparous premenopausal women (35.2% vs 9% p=0.001). PM was not associated with parity (p=0.79). Of women that had both surgeries, 20% had them concurrently and 20% had PM first. Of the 60% that underwent RRSO first, all had their second surgery within 14 months. Conclusions: BRCA mutation “previvors” have a high overall uptake of prophylactic surgery. Premenopausal women are more likely to choose PM than postmenopausal women; reasons for this are unclear. “Previvors” that choose RRSO and PM typically have both surgeries within a fairly short timeframe. With the growing population of “previvors” in the US, further study of patient preferences regarding preventative surgery and long-term consequences is needed. [Table: see text]


2020 ◽  
Vol 156 (1) ◽  
pp. 131-139
Author(s):  
Phuong L. Mai ◽  
Helen Q. Huang ◽  
Lari B. Wenzel ◽  
Paul K. Han ◽  
Richard P. Moser ◽  
...  

2020 ◽  
Author(s):  
Courtney Macdonald ◽  
Danielle Mazza ◽  
Martha Hickey ◽  
Morgan Hunter ◽  
Louise A Keogh ◽  
...  

Abstract Background This study examined why women and doctors screen for ovarian cancer (OC) contrary to guidelines. Methods Surveys, based on the Theoretical Domains Framework (TDF), were sent to women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), and family physicians (FPs) and gynecologists who organised their screening. Results 832 of 1,264 (65.8%) kConFab women responded. 126 (15.1%) had screened in the last two years. Most of these (101, 80.2%) would continue even if their doctor told them it is ineffective. For women, key OC screening motivators operated in the domains of social role and goals (staying healthy for family, 93.9%), emotion and reinforcement (peace of mind, 93.1%) and beliefs about capabilities (tests are easy to have, 91.9%). 252 of 531 (47.5%) clinicians responded; a minority (FPs 45.8%, gynecologists 16.7%) thought OC screening was useful. For gynecologists, the main motivators of OC screening operated in the domains of environmental context (lack of other screening options, 27.6%), and emotion (patient peace of mind, 17.2%, difficulty discontinuing screening, 13.8%). For FPs, the strongest motivators were in the domains of social influence (women ask for these tests, 20.7%), goals (a chance these tests will detect cancer early, 16.4%), emotion (patient peace of mind, 13.8%) and environmental context (no other OC screening options, 11.2%). Conclusion Reasons for OC screening are mostly patient driven. Clinician knowledge and practice are discordant. Motivators of OC screening encompass several domains, which could be targeted in interventions to reduce inappropriate ovarian cancer screening.


Sign in / Sign up

Export Citation Format

Share Document